CLINICAL TRIALS PROFILE FOR AKINETON
✉ Email this page to a colleague
All Clinical Trials for AKINETON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00495183 ↗ | Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence | Unknown status | Hospital Universitari Vall d'Hebron Research Institute | Phase 4 | 2009-01-01 | The aim of this study is to assess the efficacy of caffeine compared to placebo as a maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be also studied. Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.) plus biperidene (8 mg b.i.d.) caffeine (300 - 1200 mg t.i.d.) with placebo or placebo during 10 days in an in-hospital setting. |
| NCT01048138 ↗ | Use of Biperiden for the Prevention of Post-traumatic Epilepsy | Recruiting | Cristália Produtos Químicos Farmacêuticos Ltda. | Phase 3 | 2018-01-31 | There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy. |
| NCT01048138 ↗ | Use of Biperiden for the Prevention of Post-traumatic Epilepsy | Recruiting | University of Sao Paulo | Phase 3 | 2018-01-31 | There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy. |
| NCT01048138 ↗ | Use of Biperiden for the Prevention of Post-traumatic Epilepsy | Recruiting | Federal University of São Paulo | Phase 3 | 2018-01-31 | There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy. |
| NCT04945213 ↗ | Biperiden Trial for Epilepsy Prevention | Not yet recruiting | Ministry of Health, Brazil | Phase 3 | 2022-02-01 | One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI. |
| NCT04945213 ↗ | Biperiden Trial for Epilepsy Prevention | Not yet recruiting | PROADI-SUS | Phase 3 | 2022-02-01 | One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI. |
| NCT04945213 ↗ | Biperiden Trial for Epilepsy Prevention | Not yet recruiting | Hospital Sirio-Libanes | Phase 3 | 2022-02-01 | One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AKINETON
Condition Name
Clinical Trial Locations for AKINETON
Clinical Trial Progress for AKINETON
Clinical Trial Phase
Clinical Trial Sponsors for AKINETON
Sponsor Name
